Synlogic names new CEO
This article was originally published in Scrip
Synlogic, a biotechnology company focused on the development of therapeutic synthetic life, has named Dr Jose-Carlos (JC) Gutiérrez-Ramos president and CEO. Dr Gutiérrez-Ramos brings more than 20 years of experience in drug discovery and development leadership spanning the pharmaceutical and biotechnology industries as well as academia. He joins Synlogic from Pfizer where he was group senior vice-president and global head of BioTherapeutics R&D. In that role, he held responsibility for more than 25 novel programs across the full spectrum of clinical development, re-launched efforts in rare disease discovery and development, and founded the Centers for Therapeutic Innovation.